New research has found that the addition of tumour-treating fields to temozolomide maintenance improved progression-free survival (PFS) and overall survival (OS) in glioblastoma patients.
New Treatment for Glioblastoma: Addition of Tumour-Treating Fields to Maintenance Temozolomide in Glioblastoma
Glioblastoma is one of the most difficult types of cancer to treat. However, treatments are continuing to improve as new precision oncology research emerges.
Tumour-treating fields (TTFields) consist of low-intensity, alternating electric fields that are delivered by transducer arrays applied to the scalp. The tumour-treating fields modality interferes with glioblastoma cell division and organelle assembly by delivery of low-intensity alternating electric fields to the tumour.
Therefore, researchers were interested in discovering whether adding TTFields to maintenance temozolomide chemotherapy would improve PFS and OS rates for patients with glioblastoma.
A recent clinical trial investigated this question, with significant success. The trial involved 695 patients with glioblastoma who’d already completed initial radiochemotherapy and had undergone resection or biopsy.
Results were as follows: median PFS was 6.7 months in the TTFields plus temozolomide group versus 4.0 months in the temozolomide-alone group – a significant difference, no doubt. Meanwhile, median OS was 20.9 in the tumour-treating fields group versus 16.0 months in the temozolomide-alone group.
These results were not only statistically significant but were consistent with results of a previous interim analysis. Reach more about the study.
This is very encouraging news for patients with glioblastoma, since it shows that adding TTFields to maintenance temozolomide chemotherapy improves both PFS and OS rates compared to maintenance temozolomide chemotherapy alone.
Explore ALL Your Cancer Treatment Options with CTOAM
If you’d like to know whether this discovery can benefit your treatment plan, register for a Precision Second Opinion with our medical team today.
Higher survival rates, better quality of life, and fewer & less severe side effects are just some of the benefits that targeted therapies offer cancer patients. CTOAM helps you identify and access the right targeted therapies for you – for as close to free, and as close to home, as possible. Call today to ensure you’re doing the best you can for you and your family.
See how we help patients like you.
CTOAM, Precision Oncology Specialists: The future of cancer treatment, now.
Stupp et al., (2017). Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma. JAMA; 318(23) :2306-2316.on April 5, 2018
Tags: Glioblastoma, Head and Neck Cancers, Studies
Share your thoughts